One year after the Food and Drug Administration launched a voluntary pilot program to release clinical study reports, which are summaries of clinical trial data, only one company has provided any information about a drug. As a result, a group of academics is concerned the effort has stalled and is calling on the agency to make such disclosures mandatory.

Clinical study reports help form the basis for regulatory approval decisions, but disclosure has long been a flashpoint among researchers and drug makers, prompting heated debate about patient privacy, trade secrets, and improving medical research. However, regulators in other countries had taken steps to disclose these reports and the FDA touted the program as its own bid to provide greater transparency.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy